The anxiolytic etifoxine protects against convulsant and anxiogenic aspects of the alcohol withdrawal syndrome in mice

Alcohol

Volumn 43, Issue 3, 2009, Pages 197-206

  Verleye, Marc ^a   Heulard, Isabelle ^a   Gillardin, Jean Marie ^a  

^a Service de Pharmacologie   (France)

Author keywords

anxiety; convulsions; Ethanol withdrawal symptoms; etifoxine; light and dark test box; mice

Indexed keywords

ALCOHOL; ANXIOLYTIC AGENT; DIAZEPAM; ETIFOXINE; STRESAM; UNCLASSIFIED DRUG;

ALCOHOL BLOOD LEVEL; ALCOHOL CONSUMPTION; ALCOHOL WITHDRAWAL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY DISORDER; ARTICLE; ATAXIA; AVERSION; CONTROLLED STUDY; CONVULSION; DISEASE SEVERITY; DOSE RESPONSE; LOCOMOTION; MALE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; TRANQUILIZING ACTIVITY; TREMOR;

ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; DIAZEPAM; ETHANOL; GABA AGONISTS; MALE; MICE; MODELS, ANIMAL; MOTOR ACTIVITY; OXAZINES; RECEPTORS, GABA-A; SEIZURES; SUBSTANCE WITHDRAWAL SYNDROME;

ANIMALIA; MUS;

EID: 64849098269     PISSN: 07418329     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.alcohol.2009.02.003     Document Type: Article

References (70)

1. Barnes N.M., Costall B., Kelly M.E., Onaivi E.S., and Naylor R.J. Ketotifen and its analogues reduce aversive responding in the rodent. Pharmacol. Biochem. Behav. 37 (1990) 785-793
2. Bayard M., McIntyre J., Hill K.R., and Woodside Jr. J. Alcohol withdrawal syndrome. Am. Fam. Physician 69 (2004) 1443-1450
3. Becker H.C. Animal models of alcohol withdrawal. Alcohol Res. Health 24 (2000) 105-113
4. Biggio G., Concas A., Follesa P., Sanna E., and Serra M. Stress, ethanol, and neuroactive steroids. Pharmacol. Ther. 116 (2007) 140-171
5. Boissier J.R., Simon P., Zaczinska M., and Fichelle J. Experimental psychopharmacologic study of a new psychotropic drug, 2-ethylamino-6-chloro-4-methyl-4-phenyl-4H-3,1-benzoxazine. Therapie 27 (1972) 325-338
6. Bourin M., and Hascoet M. The mouse light/dark box test. Eur. J. Pharmacol. 463 (2003) 55-65
7. Bucher T., and Redetzki H. Specific photometric determination of ethyl alcohol based on an enzymatic reaction. Klin. Wochenschr. 29 (1951) 615-616
8. Chandler L.J., Harris R.A., and Crews F.T. Ethanol tolerance and synaptic plasticity. Trends Pharmacol. Sci. 19 (1998) 491-495
9. Chastain G. Alcohol, neurotransmitter systems, and behaviour. J. Gene. Psychol. 133 (2006) 329-335
10. Costall B., Jones B.J., Kelly M.E., Naylor R.J., Onaivi E.S., and Tyers M.B. Ondansetron inhibits a behavioural consequence of withdrawing from drugs of abuse. Pharmacol. Biochem. Behav. 36 (1990) 339-344
11. Costall B., Kelly M.E., and Naylor R.J. The anxiolytic and anxiogenic actions of ethanol in a mouse model. J. Pharm. Pharmacol. 40 (1988) 197-202
12. Crawley J., and Goodwin F.K. Preliminary report of a simple animal behavior model for the anxiolytic effects of benzodiazepines. Pharmacol. Biochem. Behav. 13 (1980) 167-170
13. Devaud L.L., Smith F.D., Grayson D.R., and Morrow A.L. Chronic ethanol consumption differentially alters the expression of gamma-aminobutyric acidA receptor subunit mRNAs in rat cerebral cortex: competitive, quantitative reverse transcriptase-polymerase chain reaction analysis. Mol. Pharmacol. 48 (1995) 861-868
14. Diana M., Pistis M., Carbonni S., Gessa G.L., and Rossetti Z.L. Profound decrement of mesolimbic dopaminergic neuronal activity during ethanol withdrawal syndrome in rats: electrophysiological and biochemical evidence. Proc. Natl. Acad. Sci. 90 (1993) 7966-7969
15. File S.E., Zharkovsky A., and Hitchcott P.K. Effects of nitrendipine, chlordiazepoxide, flumazenil and baclofen on the increased anxiety resulting from alcohol withdrawal. Prog. Neuropsychopharmacol. Biol. Psychiatry 16 (1992) 87-93
16. Finn D.A., and Crabbe J.C. Exploring alcohol withdrawal syndrome. Alcohol Health Res. World 21 (1997) 149-156
17. Follesa P., Biggio F., Mancuso L., Cabras S., Caria S., Gorini G., et al. Ethanol withdrawal-induced up-regulation of the alpha2 subunit of the GABAA receptor and its prevention by diazepam or gamma-hydroxybutyric acid. Brain Res. Mol. Brain Res. 120 (2004) 130-137
18. Follesa P., Biggio F., Talani G., Murru L., Serra M., Sanna E., et al. Neurosteroids, GABAA receptors, and ethanol dependence. Psychopharmacology (Berl) 186 (2006) 267-280
19. Follesa P., Mostallino M.C., Biggio F., Gorini G., Caria S., Busonero F., et al. Distinct patterns of expression and regulation of GABA receptors containing the delta subunit in cerebellar granule and hippocampal neurons. J. Neurochem. 94 (2005) 659-671
20. Gatch M.B., and Lal H. Pharmacological treatment of alcoholism. Prog. Neuropsychopharmacol. Biol. Psychiatry 22 (1998) 917-944
21. Goldstein D.B. An animal model for testing effects of drugs on alcohol withdrawal reactions. J. Pharmacol. Exp. Ther. 183 (1972) 14-22
22. Goldstein D.B., and Pal N. Alcohol dependence produced in mice by inhalation of ethanol: grading the withdrawal reaction. Science 172 (1971) 288-290
23. Golovko A.I., Golovko S.I., Leontieva L.V., and Zefirov S.Y. The influence of ethanol on the functional status of GABA(A) receptors. Biochemistry (Mosc) 67 (2002) 719-729
24. Grobin A.C., Matthews D.B., Devaud L.L., and Morrow A.L. The role of GABA(A) receptors in the acute and chronic effects of ethanol. Psychopharmacology (Berl) 139 (1998) 2-19
25. Haefely W., Martin J.R., and Schoch P. Novel anxiolytics that act as partial agonists at benzodiazepine receptors. Trends Pharmacol. Sci. 11 (1990) 452-456
26. Hamon A., Morel A., Hue B., Verleye M., and Gillardin J.M. The modulatory effects of the anxiolytic etifoxine on GABA(A) receptors are mediated by the beta subunit. Neuropharmacology 45 (2003) 293-303
27. Harris R.A. Ethanol actions on multiple ion channels: which are important?. Alcohol Clin. Exp. Res. 23 (1999) 1563-1570
28. Harris R.A., Mihic S.J., and Valenzuela C.F. Alcohol and benzodiazepines: recent mechanistic studies. Drugs Alcohol Depend. 51 (1998) 155-164
29. Johnson B.A. An overview of the development of medications including novel anticonvulsants for the treatment of alcohol dependence. Expert Opin. Pharmacother. 5 (2004) 1943-1955
30. Jung M.E., Wallis C.J., Gatch M.B., and Lal H. Abecarnil and alprazolam reverse anxiety-like behaviors induced by ethanol withdrawal. Alcohol 21 (2000) 161-168
31. Kang M.H., Spigelman I., and Olsen R.W. Alteration in the sensitivity of GABA(A) receptors to allosteric modulatory drugs in rat hippocampus after chronic intermittent ethanol treatment. Alcohol Clin. Exp. Res. 22 (1998) 2165-2173
32. Kliethermes C.L. Anxiety-like behaviors following chronic ethanol exposure. Neurosci. Biobehav. Rev. 28 (2005) 837-850
33. Kokka N., Sapp D.W., Taylor A.M., and Olsen R.W. The kindling model of alcohol dependence: similar persistent reduction in seizure threshold to pentylenetetrazol in animals receiving chronic ethanol or chronic pentylenetetrazol. Alcohol Clin. Exp. Res. 17 (1993) 525-531
34. Korpi E.R., Gründer G., and Lüddens H. Drug interactions at GABA(A) receptors. Prog. Neurobiol. 67 (2002) 113-159
35. Kruse H.J., and Kuch H. Etifoxine: evaluation of its anticonvulsant profile in mice in comparison with sodium valproate, phenytoin and clobazam. Arzneimittelforschung 35 (1985) 133-135
36. Kumar S., Fleming R.L., and Morrow A.L. Ethanol regulation of gamma-aminobutyric acid A receptors: genomic and nongenomic mechanisms. Pharmacol. Ther. 101 (2004) 211-226
37. Liang J., Zhang N., Cagetti E., Houser C.R., Olsen R.W., and Spigelman I. Chronic intermittent ethanol-induced switch of ethanol actions from extrasynaptic to synaptic hippocampal GABAA receptors. J. Neurosci. 26 (2006) 1749-1758
38. Littleton J. Neurochemical mechanisms underlying alcohol withdrawal. Alcohol Health Res. World 22 (1998) 13-24
39. Longone P., Rupprecht R., Manieri G.A., Bernardi G., Romeo E., and Pasini A. The complex roles of neurosteroids in depression and anxiety disorders. Neurochem. Int. 52 (2008) 596-601
40. Majewska M.D. Neurosteroids: endogenous bimodal modulators of the GABAA receptor. Mechanism of action and physiological significance. Prog. Neurobiol. 38 (1992) 379-395
41. Mayo-Smith M.F. Pharmacological management of alcohol withdrawal. A meta-analysis and evidence-based practice guideline. American Society of Addiction Medicine Working Group on Pharmacological Management of Alcohol Withdrawal. JAMA 278 (1997) 144-151
42. Mehta A.K., and Ticku M.K. Ethanol potentiation of GABAergic transmission in cultured spinal cord neurons involves gamma-aminobutyric acidA-gated chloride channels. J. Pharmacol. Exp. Ther 246 (1988) 558-564
43. Mhatre M., and Ticku M.K. Chronic ethanol treatment upregulates the GABA receptor beta subunit expression. Brain Res. Mol. Brain Res. 23 (1994) 246-252
44. Mhatre M.C., Pena G., Sieghart W., and Ticku M.K. Antibodies specific for GABAA receptor alpha subunits reveal that chronic alcohol treatment down-regulates alpha-subunit expression in rat brain regions. J. Neurochem. 61 (1993) 1620-1625
45. Micallef J., Soubrouillard C., Guet F., Le Guern M.E., Alquier C., Bruguerolle B., et al. A double blind parallel group placebo controlled comparison of sedative and amnesic effects of etifoxine and lorazepam in healthy subjects. Fundam. Clin. Pharmacol. 15 (2001) 209-216
46. Millan M.J. The neurobiology and control of anxious states. Prog. Neurobiol. 70 (2003) 83-244
47. A receptor positive allosteric modulator: In vitro actions, pharmacokinetic properties and in vivo anxiolytic efficacy. J. Pharmacol. Exp. Ther. 327 (2008) 954-968
48. Montpied P., Morrow A.L., Karanian J.W., Ginns E.I., Martin B.M., and Paul S.M. Prolonged ethanol inhalation decreases gamma-aminobutyric acidA receptor alpha subunit mRNAs in the rat cerebral cortex. Mol. Pharmacol. 39 (1991) 157-163
49. Morrow A.L., Porcu P., Boyd K.N., and Grant K.A. Hypothalamic-pituitary-adrenal axis modulation of GABAergic neuroactive steroids influences ethanol sensitivity and drinking behavior. Dialogues Clin. Neurosci. 8 (2006) 463-477
50. Naassila M., Legrand E., d'Alche-Biree F., and Daoust M. Cyamemazine decreases ethanol intake in rats and convulsions during ethanol withdrawal syndrome in mice. Psychopharmacology (Berl) 140 (1998) 421-428
51. Nachman M., Larue C., and Le Magnen J. The role of olfactory and orosensory factors in the alcohol preference of inbred strains of mice. Physiol. Behav. 6 (1971) 53-59
52. Nguyen N., Fakra E., Pradel V., Jouve E., Alquier C., Le Guern M.E., et al. Efficacy of etifoxine compared to lorazepam monotherapy in the treatment of patients with adjustment disorders with anxiety: a double-blind controlled study in general practice. Hum. Psychopharmacol. 21 (2006) 139-149
53. Olsen R.W., Hanchar H.J., Meera P., and Wallner M. GABAA receptor subtypes: the "one glass of wine" receptors. Alcohol 41 (2007) 201-209
54. Overstreet D.H., Knapp D.J., and Breese G.R. Accentuated decrease in social interaction in rats subjected to repeated ethanol withdrawals. Alcohol Clin. Exp. Res. 26 (2002) 1259-1268
55. A receptor subtypes: dissecting their pharmacological functions. Trends Pharmacol. Sci. 22 (2001) 188-194
56. Saitz R., and O'Malley S.S. Pharmacotherapies for alcohol abuse. Withdrawal and treatment. Med. Clin. North Am. 81 (1997) 881-907
57. Schlichter R., Rybalchenko V., Poisbeau P., Verleye M., and Gillardin J. Modulation of GABAergic synaptic transmission by the non-benzodiazepine anxiolytic etifoxine. Neuropharmacology 39 (2000) 1523-1535
58. Servant D., Graziani P.L., Moyse D., and Parquet P.J. Treatment of adjustment disorder with anxiety: efficacy and tolerance of etifoxine in a double-blind controlled study]. Encephale 24 (1998) 569-574
59. Sieghart W. Structure, pharmacology, and function of GABAA receptor subtypes. Adv. Pharmacol. 54 (2006) 231-263
60. Smolen T.N., and Smolen A. Blood and brain ethanol concentrations during absorption and distribution in long-sleep and short-sleep mice. Alcohol 6 (1989) 33-38
61. Stanford S.C. Central noradrenergic neurons and stress. Pharmacol. Ther. 68 (1995) 297-342
62. Timpl P., Spanagel R., Sillaber I., Kresse A., Reul J.M., Stalla G.K., et al. Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1. Nat. Genet. 19 (1998) 162-166
63. Verleye M., Akwa Y., Liere P., Ladurelle N., Pianos A., Eychenne B., et al. The anxiolytic etifoxine activates the peripheral benzodiazepine receptor and increases the neurosteroid levels in rat brain. Pharmacol. Biochem. Behav. 82 (2005) 712-720
64. Verleye M., and Gillardin J.M. Effects of etifoxine on stress-induced hyperthermia, freezing behavior and colonic motor activation in rats. Physiol. Behav. 82 (2004) 891-897
65. Verleye M., Schlichter R., and Gillardin J.M. Interactions of etifoxine with the chloride channel coupled to the GABA(A) receptor complex. Neuroreport 10 (1999) 3207-3210
66. Wallis C.J., Rezazadeh S.M., and Lal H. GM1 ganglioside reduces ethanol intoxication and the development of ethanol dependence. Alcohol 12 (1995) 573-580
67. Watson W.P., and Little H.J. Interactions between diltiazem and ethanol: differences from those seen with dihydropyridine calcium channel antagonists. Psychopharmacology (Berl) 114 (1994) 329-336
68. Watson W.P., and Little H.J. Selectivity of the protective effects of dihydropyridine calcium channel antagonists against the ethanol withdrawal syndrome. Brain Res. 930 (2002) 111-122
69. Watson W.P., Robinson E., and Little H.J. The novel anticonvulsant, gabapentin, protects against both convulsant and anxiogenic aspects of the ethanol withdrawal syndrome. Neuropharmacology 36 (1997) 1369-1375
70. Whittington M.A., Lambert J.D., and Little H.J. Increased NMDA receptor and calcium channel activity underlying ethanol withdrawal hyperexcitability. Alcohol Alcohol. 30 (1995) 105-114